No matter where you are in the preclinical lifecycle of your small molecule candidates, Eurofins Discovery provides innovative approaches and expert scientists to accelerate your program. With the end goals of approval and adoption in sight, we integrate specialty platforms, cutting-edge equipment, and an assertive approach to propel you through early discovery, target identification, hit finding, lead optimization, mechanistic studies and preclinical safety and toxicity assessments.
We’re known for delivering high-quality data, conscientious communication with client-partners, and a global team readily available across time zones to consult with you on both target-based and target-agnostic approaches. Whether you need access to specialty human-centric platforms for preclinical discovery, or off-the-shelf solutions, we guarantee robust, data-driven insights to advance your research to the finish line.
SOLUTIONS
Eurofins Discovery built its industry-leading reputation on successfully delivering best-in-class drug discovery services to any organization, large or small. No matter where you are in the preclinical process—or if you need full end-to-end solutions—our experts support you every step of the way with purpose, precision, and innovation.
As a global leader in drug discovery for over 40 years, we have strategically amassed a deep and broad range of over +10,000 assays for every type of research, as well as a full team of industry experts across disciplines to collaborate with you. Delve into all the ways we can work together by choosing the best path forward for you from our comprehensive services.
Small Molecules
Biotherapeutics
Integrated Drug Discovery
Therapeutic Areas
Research Phase
Custom Solutions
Small Molecules
Key Areas
All Target-based Assays
Advance your drug discovery with our unparalleled portfolio of off-the-shelf assays against challenging targets, LeadHunter.
GPCRs
G-protein Coupled Receptors (GPCRs) play an important role in disease pathogenesis and constitute the largest family of transmembrane proteins in the human genome, making them one of the most attractive therapeutic target classes.
Kinases
Complete your custom protein production, assay development, screening, and kinase selectivity profiling needs with confidence.
Ion Channels
Investigate ion channel targets and/or assess drug safety profiles early in the drug discovery process.
Chemistry
Our chemistry services drive preclinical success by combining synthetic, computational, medicinal, and analytical chemistry with biology, delivering optimized molecules through an integrated, data-driven approach. With labs located strategically in Spain, US & India, we provide flexible Chemistry services to accelerate your Drug Discovery program.
Translational Biology
Phenotypic drug discovery gives you a head start on clinical success with translationally relevant biomarkers as functional readouts for insights on mechanism of action, efficacy, and toxicity assessments.
Safety Pharmacology
Develop Safer Preclinical Candidates with Industry-leading, Reliable and Robust In Vitro Safety Assays and Panels
ADME Toxicology
Gain an early understanding of your lead compounds’ drug-like properties of absorption, distribution, metabolism, and excretion (ADME), as well as potential toxicities, from our growing portfolio of over 600 assays.
In Vivo Pharmacology
Our technical experts and partner lab can customize in vivo testing for your specific study design or disease model, creating an efficient process that propels you closer to the clinic.
Targeted Protein Degradation
The generic approach to target disease-causing proteins is through small molecules that bind to and inhibit the enzymatic activity of the protein.
AI-Driven Drug Discovery
Intelligent partner for AI-enabled drug discovery with wet lab validation. Eurofins Discovery refines predictions and accelerates hit-to-lead programs.
Questions? Contact Us
You can easily get in touch with a Eurofins Discovery Expert or get help from our Customer Service team. Reach out with questions, or to discuss your specific discovery challenges.
